Daiichi Sankyo Company, Limited (TYO:4568)
3,308.00
-72.00 (-2.13%)
Jun 20, 2025, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
100.73M JPY
Profits / Employee
15.79M JPY
Market Cap
6,309.29B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Chugai Pharmaceutical | 5,026 |
Takeda Pharmaceutical Company | 49,281 |
HOYA Corporation | 37,909 |
Otsuka Holdings | 35,338 |
Astellas Pharma | 13,643 |
Olympus | 28,838 |
Shionogi & | 4,955 |
Sysmex | 10,042 |
Daiichi Sankyo Company News
- 2 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 10 days ago - DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - Benzinga
- 17 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial - Benzinga
- 17 days ago - ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial - Benzinga
- 18 days ago - DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer - Benzinga
- 19 days ago - ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial - Benzinga
- 21 days ago - Merck, Daiichi Sankyo pull marketing application for lung cancer therapy - Seeking Alpha
- 4 weeks ago - Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO - Business Wire